Mazdutide MAZ

An experimental injectable weight-loss and diabetes drug in human trials, mostly in China. Results show weight loss and blood sugar improvements comparable to leading approved drugs, though it isn't approved outside of trials yet.

Also known as IBI362, LY3305677

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved in the US; approved in China at doses under evaluation

Reported range Phase III trials: 4-9 mg once weekly

Route Subcutaneous injection

Frequency Once weekly

Duration Chronic/ongoing (per approved Chinese labeling) or trial durations elsewhere

A GLP-1/glucagon dual agonist approved in China (as Mounjaro-class competitor) for weight management; not FDA-approved in the US as of this writing.

Where this comes from Chinese regulatory/clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.